In this episode, Dr. Andrew Cutler interviews Dr. Karl Doghramji on best practices for the treatment and management of insomnia. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD22-Sleep Learning Objectives: After completing this educational activity, you should be better able to: Utilize assessment tools in the diagnosis of insomnia Address challenges in the pharmacologic treatment of insomnia Implement evidence-based pharmacological treatments for insomnia Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics.  Credit Types. The following are being offered for this activity: Nurse Practitioner: ANCC contact hours Pharmacy: ACPE application-based contact hours Physician: ACCME AMA PRA Category 1 Credits ™ Physician Assistant: AAPA Category 1 CME credits Psychology: APA CE credits Social Work: ASWB-ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content were required to disclose all relevant financial relationships. Any potential conflicts of interest were identified and mitigated prior to the activity being planned, developed, or presented. InterviewerAndrew J. Cutler, MD  Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NYChief Medical Officer, Neuroscience Education Institute, Carlsbad, CAConsultant/Advisor: AbbVie, Acadia, AiCure, Alfasigma, Alkermes, Allergan, Atentiv, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris IntervieweeKarl Doghramji, MDProfessor, Department of Psychiatry & Human Behavior; Associate Professor, Departments of Neurology and of Medicine; Medical Director, Jefferson Sleep Disorders Center; Program Director, Fellowship in Sleep Medicine; Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PAResearch/Grant: Harmony, Inspire Consultant/Advisor: Axsome, Eisai, Jazz, Harmony, Idorsia, Imbrium, Inspire Stockholder: Merck Pre-Interview AuthorSabrina K. Bradbury-Segal, PhDMedical Writer, Neuroscience Education Institute, Carlsbad, CANo financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competency, and strategies for understanding and reducing implicit bias can be found in this handout. Support: This activity is supported by an unrestricted educational grant from Eisai. Released: August 31, 2022          CE credit expires: August 31, 2025

What is the difference between psychopathy and antisocial personality? What is known about gender differences when it comes to antisocial personality disorder? In this episode, Dr. Andrew Cutler interviews Dr. James Knoll about how to diagnose and treat antisocial personality disorder. With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on decriminalizing mental illness. Episodes to be released under this theme include: Part 1: Decriminalizing Mental Illness with Dr. Katherine Warburton Part 2: The Antisocial Personality Disorder Spectrum: Diagnosis and Treatment with Dr. James Knoll Part 3: Intensive Level Care for Violent Patients with Serious Mental Illness with Dr. Carolina Klein Subscribe to the NEI Podcast, so that you don’t miss another episode!

In this episode, we take a look back at Dr. Roger McIntyre’s presentation on the treatment spectrum for depression and mania. In this sneak peek, Dr. McIntyre focuses on the current treatments that are available for the bipolar disorder spectrum. He addresses the implications of comorbid substance abuse with respect to pharmacological treatments. He also discusses lifestyle factors that can be preventative against cognitive decline associated with mood disorders. Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre was named by Thomson Reuters in 2014 and 2015, as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade. Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders, notably cognitive function and medical comorbidity. His works broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment. Dr. McIntyre is a contributor to the “Florida Medicaid Drug Therapy Management Program for Behavioral Health: Guidelines for the treatment of adults with Major Depressive Disorder and Bipolar Disorder”. Dr. McIntyre is also the co-chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force on the Treatment of Comorbidity in Adults with Major Depressive Disorder or Bipolar Disorder and as well a contributor to the “CANMAT Guidelines for the Treatment of Depressive Disorders and Bipolar Disorders”. Dr. McIntyre has published hundreds of peer-reviewed articles and has edited and/or co-edited several textbooks on mood disorders.

In today’s CME episode, Dr. Andrew Cutler will be interviewing Dr. Leslie Citrome about the safety and efficacy of VMAT2 inhibitors for the treatment of tardive dyskinesia. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD22-TD03 Learning Objectives: After completing this educational activity, you should be better able to: Recognize the safety and efficacy of VMAT2 inhibitors for the treatment of tardive dyskinesia Individualize treatment regimens for patients with tardive dyskinesia, utilizing FDA-approved medications Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. Credit Types. The following are being offered for this activity: Nurse Practitioner: ANCC contact hours Pharmacy: ACPE application-based contact hours Physician: ACCME AMA PRA Category 1 Credits ™ Physician Assistant: AAPA Category 1 CME credits Psychology: APA CE credits Social Work: ASWB-ACE CE credits Non-Physician Member of the Mental Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Potential conflicts of interest are identified and mitigated prior to the activity being planned, developed, or presented. InterviewerAndrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie/Allergan, Acadia, Alfasigma, Biogen, BioXcel, Boehringer Ingelheim, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, Neurocrine, Noven, Otsuka, Relmada, Sage, Sunovion, Supernus, Teva Speakers Bureau: AbbVie/Allergan, Acadia, Alfasigma, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Teva   IntervieweeLeslie Citrome, MD, MPH Clinical Professor, Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY Consultant/Advisor: AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Eisai, Enteris BioPharma, HLS Therapeutics, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Lyndra, Medavante-ProPhase, Merck, Neurocrine, Novartis, Noven, Otsuka, Ovid, Relmada, Reviva, Sage, Sunovion, Supernus, Teva, University of Arizona Speakers Bureau: AbbVie/Allergan, Acadia, Alkermes, Angelini, Eisai, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Takeda, Teva Stockholder: Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, Pfizer, Reviva (options)   Pre-Interview AuthorSabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose.   The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competency and strategies for understanding and reducing the impact of implicit bias can be found in this handout. Support: This activity is supported by an unrestricted educational grant from Neurocrine Biosciences. Released: July 27, 2022     CME/CE credit expires: July 27, 2025

In this episode, Dr. Andrew Cutler interviews Dr. Katherine Warburton about the history of criminalization of serious mental illness, the efforts to decriminalize mental illness, and the development and success of diversion programs. Dr. Katherine Warburton is Medical Director/Deputy Director of Clinical Operations for the California Department of State Hospitals. Prior to that, she was the Chief of Forensic Psychiatry at Napa State Hospital. She is on the volunteer clinical faculty of the UC Davis Division of Psychiatry and the Law. With this special series, brought to you by the NEI Podcast, we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on decriminalizing mental illness. Episodes to be released under this theme include: Part 1: Decriminalizing Mental Illness Part 2: Managing the Unique Challenges of Correctional Psychiatry Part 3: The Intensive Treatment Setting and Special Cases in Forensic Psychiatry Subscribe to the NEI Podcast so that you don’t miss another episode! Link to “Decriminalizing Mental Illness” by Drs. Warburton and Stahl: https://www.amazon.com/Decriminalizing-Mental-Illness-Katherine-Warburton/dp/1108826954/ref=sr_1_1?crid=18XJ6RE7Y5X5M&keywords=warburton+stahl&qid=1657746214&sprefix=warburton+stahl%2Caps%2C112&sr=8-1

How did Fountain House come to be? What is the history behind it? What does it mean to be a Fountain House member? In this fascinating podcast, we hear from three experts who work with Fountain House to reduce stigma for people with serious mental illness, improve education, foster a community and provide resources for members of Fountain House to thrive and live fulfilling lives. Fountain House is a national mental health nonprofit fighting to improve health, increase opportunity, and end social and economic isolation for people impacted by mental illness. Drawing on more than 200 community-based social rehabilitative programs inspired by Fountain House and known as clubhouses - to reflect an insistence on belonging and acceptance - in nearly 40 states and with more than 60,000 members, they are leading a national movement for the dignity and rights of people with serious mental illness. Jeanie Tse, MD is the Senior Medical Director at Fountain House and an Associate Professor of Psychiatry at the NYU School of Medicine. She brings to Fountain House her expertise in integrated health care for people with serious mental illnesses, developed in the course of her work as the former Chief Medical Officer at the Institute for Community Living. She has a special interest in disrupting the impact of trauma on health outcomes, with an overarching aim to “bridge the gap” between academic psychiatry and the clinical challenges of under-resourced communities.  Francesca Pernice, PhD is an associate professor in Educational Psychology and Director of Counseling Psychology at Wayne University's College of Education. Her areas of expertise include social and interpersonal relationships, clubhouse community recovery programs, recovery from serious mental illness, and research in mental health, and program evaluation. She instructs graduate courses in the area of adult psychopathology, ethics, and educational psychology. She serves as advisor for PhD students in the School Psychology PhD Concentration and Learning and Instructional Sciences PhD concentration within the department of Educational Psychology. Her areas of expertise include family psychoeducation about serious mental illness, and research of psychiatric rehabilitation programs known as Fountain House Clubhouses. Cyrus Daniel Napolitano is a member of Fountain House who has served on their Board of Directors, the Council, a think-tank that focuses on innovation, training, education, research, public policy, advocacy, and technology. He is currently Co-Director of the Clubhouse New York Coalition that represents 14 clubhouses in NYC and in New Jersey. He is also working to foster the development of community-based mental health programs in low- to middle-income countries.  Fountain House website: https://www.fountainhouse.org/

In this episode, Dr. Andrew Cutler interviews Dr. Tiffany Greenwood about the intersection of genetics, personality traits, temperament and cognitive traits in bipolar disorder and creativity. What is psychiatric genetics? What is known about dopamine’s role in creativity? Dr. Tiffany Greenwood address these questions and much more. Dr. Greenwood received her B.S. in Molecular Biology and her Ph.D. in Biomedical Sciences from UC San Diego, with an emphasis in psychiatric genetics. She then augmented her molecular genetic background with postdoctoral training in applied statistical genetics and acquired supplemental training in clinical psychopathology through a Career Development Award from the National Institute of Mental Health (NIMH). She joined the Department of Psychiatry at UC San Diego in 2007 and is currently an Associate Professor. As the Director of the Laboratory for Psychiatric Spectrum Research, Dr. Greenwood’s research focuses on the use of dimensional and intermediate phenotypes, as well as clinical subphenotypes, to reduce clinical heterogeneity and refine the genetic signal. Such measures provide increased specificity, both within and across diagnostic categories, as well as a better reflection of the underlying biological processes. In this vein, Dr. Greenwood participates in a number of large-scale collaborations aimed at identifying genetic risk variants for psychiatric illness, including the Consortium on the Genetics of Schizophrenia (COGS), the Bipolar Genome Study (BiGS), and the Psychiatric Genomics Consortium (PGC). Her research in this area has been supported by a NARSAD Young Investigator Award for the development and utilization of a customized candidate gene array for schizophrenia and related phenotypes, as well as a K01 from the NIMH aimed at quantifying and interpreting the overlapping and unique aspects of bipolar disorder and schizophrenia. Dr. Greenwood has served as a Principal Investigator or Co-Investigator on a number of University and NIH-funded grants, including a current study exploring bipolar disorder as a dimensional phenotype existing at the extreme of normal population variation in positive traits, such as temperament, personality, creativity, and cognitive flexibility. Dr. Greenwood also recently received funding for a pilot project to implement a comprehensive screening and risk assessment program at UC San Diego. This project aims identify behavioral, environmental, and genetic factors associated with risk for mental health conditions, particularly mood disorders and suicide, and develop a risk prediction model to be used for early intervention. With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology. Episodes to be released under this theme include: Part 1: The Lightning in the Storm: Creativity in Bipolar Disorder Part 2: Nikola Tesla’s Evil Twins: Genius and Madness with Marko Perko Part 3: History of Creative Famous Individuals with Bipolar Disorder Subscribe to the NEI Podcast, so that you don’t miss another episode!

How has your work in psychiatry consulting and education made a difference in fighting racism on both the individual and structural level? What is your book “Social (In)Justice and Mental Health” about? In this episode, Dr. Sarah Vinson shares her extensive experience and perspective on the intersection between child and adolescent psychiatry, forensics, and the fight for social justice in mental health.   Dr. Sarah Y. Vinson is a physician who is triple-board certified in adult, child & adolescent, and forensic psychiatry. She is the founder of the Lorio Psych Group, an Atlanta, GA based mental health practice providing expert care and consultation. Dr. Vinson is also the founder of Lorio Forensics, which provide consultation in a wide variety of cases in criminal, civil and family court cases. After graduating from medical school at the University of Florida with Research Honors and as an Inductee in the Chapman Humanism Honors Society, she completed her general psychiatry training at Cambridge Health Alliance/Harvard Medical School. While there, she also received specialized training in trauma through the Victims of Violence Program. She then returned to the South to complete fellowships in both child & adolescent and forensic psychiatry at Emory University School of Medicine. In addition to providing mental health care services such as psychotherapy, consultation and psychopharmacology through her private practice, Dr. Vinson is an Associate Clinical Professor of Psychiatry and Pediatrics at Morehouse School of Medicine. Just two years after joining the faculty she was honored as Psychiatry and Faculty of the Year in 2015. She is also Adjunct Faculty at Emory University School of Medicine. She has been elected and/or appointed to national and statewide office by her professional peers. She is the Past President of the Georgia Council on Child and Adolescent Psychiatry, and the Treasurer of the Georgia Psychiatric Physicians Association. Additionally, she is an Advisor for the Judges Psychiatry Leadership Initiative.  She has been a speaker at national conferences including the American Psychiatric Association Annual Meeting, the American Academy of Child and Adolescent Psychiatry Annual Meeting and The National Urban League Annual Meeting. Dr. Vinson has received numerous awards in recognition of her service and leadership including the University of Florida College of Medicine Outstanding Young Alumna Award and the APA Jeanne Spurlock Minority Fellowship Alumna Achievement Award. Resources: https://drsarahvinson.com/ Link to “Social (In) Justice in Mental Health”: https://www.amazon.com/Social-Injustice-Mental-Health-Ruth/dp/1615373381/ref=sr_1_1?dchild=1&keywords=social%20injustice%20and%20mental%20health&qid=1608052484&sr=8-1

In this episode, Dr. Andrew Cutler interviews Dr. Diana Perkins on best practices for shared decision making and patient education. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD22-TD02 Learning Objectives: After completing this educational activity, you should be better able to: Educate patients and family members with mood disorders and schizophrenia about the symptoms of tardive dyskinesia Address psychosocial and quality-of-life concerns related to tardive dyskinesia in patients with mood disorders and schizophrenia Include patients, caregivers, and family members in shared decision-making when applicable to optimize patient outcomes before and during of treatment of tardive dyskinesia Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics.  Credit Types. The following are being offered for this activity: Nurse Practitioner (ANCC): contact hours Pharmacy (ACPE): knowledge-based contact hours   Physician (ACCME): AMA PRA Category 1 Credits ™ Physician Assistant (AAPA): Category 1 CME credits Psychology (APA): CE credits Social Work (ASWB-ACE): ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Potential conflicts of interest are identified and resolved prior to the activity being presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie/Allergan, Acadia, Alfasigma, Biogen, BioXcel, Boehringer Ingelheim, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, Neurocrine, Noven, Otsuka, Relmada, Sage, Sunovion, Supernus, Teva  Speakers Bureau: AbbVie/Allergan, Acadia, Alfasigma, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Teva Interviewee Diana Perkins, MD, MPH Professor, Department of Psychiatry; Medical Director, Outreach and Support Intervention Services; University of North Carolina School of Medicine, Chapel Hill, NC  Consultant/Advisor: Alkermes, Karuna  Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies, and strategies for understanding and reducing implicit bias can be found in this can be found in this linked handout. Support: This activity is supported by an unrestricted educational grant from Neurocrine Biosciences. Released: May 27, 2022          CE credit expires: May 27, 2025  

In this episode, Dr. Andrew Cutler interviews Mr. Marko Perko and Dr. Stephen Stahl about their newly released book “Tesla: His Tremendous and Troubled Life” and the intersection between Tesla’s genius, creativity, and bipolar disorder. How is your book unique from any book that’s been written on Tesla before? What is the main message that you’d like readers to take away from this book? In this episode Mr. Perko and Dr. Stahl address these questions and much more! Marko Perko is a graduate of the University of Southern California. He has always had an insatiable thirst for knowledge of all types, and as such, he is highly regarded as a modern-day Renaissance man, author, historian, polymath, polemicist, and history communicator. He is the author of the critically acclaimed and wildly popular book “Did You Know That . . .?” He is also a novelist and the writer of an international bestselling knowledge-based board game, as well as the creator of the Cultural Enrichment Programs education series, and a software developer―Krypti.com. Perko has written for and edited numerous publications, and he has worked as a columnist, speechwriter, composer, musician, lecturer, and playwright. He is a member of The Authors Guild; the Biographers International Organization; the American Society of Composers, Authors and Publishers; Broadcast Music, Inc.; the Institution of Engineering and Technology; the British Library; and the Organization of American Historians. With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology. Episodes to be released under this theme include: Part 1: The Lightning in the Storm: Creativity in Bipolar Disorder Part 2: Nikola Tesla’s Evil Twins: Genius and Madness with Marko Perko Part 3: History of Creative Famous Individuals with Bipolar Disorder Subscribe to the NEI Podcast, so that you don’t miss another episode!   Link to “Tesla: His Tremendous and Troubled Life”: https://www.amazon.com/Tesla-His-Tremendous-Troubled-Life-ebook/dp/B09QMPH6MG/ref=sr_1_1?crid=O0UAHNGC8Z0J&keywords=tesla+by+marko+perko&qid=1652729759&sprefix=tesla+by+marko+perko%2Caps%2C113&sr=8-1